Chapter 10 - Targeting Transition Metals for Neuroprotection in Alzheimer’s Disease

https://doi.org/10.1016/B978-0-12-803690-7.00010-7Get rights and content

Abstract

Alzheimer’s disease (AD) is a prevalent, devastating, and therapeutically intractable disease of the elderly. Amyloid beta and tau proteins are the main drivers of neurodegeneration in this disease, but drugs targeting these proteins have not been effective in clinical trial so far. The transition metals, iron, copper, and zinc, are also implicated in Alzheimer’s pathogenesis and are alternate drug targets. Here we outline the pathological changes to these transition metals in AD, and discuss the rational and recent attempts to therapeutically target these for disease modification in AD.

References (0)

Cited by (1)

  • Metal ion coordination in peptide fragments of neurotrophins: A crucial step for understanding the role and signaling of these proteins in the brain

    2021, Coordination Chemistry Reviews
    Citation Excerpt :

    The stability constant value of each species is the only parameter that provides the affinity of a metal ion for a ligand on a quantitative basis; in addition, this parameter makes it possible to obtain the distribution of all existing species over a given pH interval and to compare the affinity of a metal ion for the ligand of interest with that of other ligands. This is of crucial importance in order to improve the picture of the real situation and may help designing synthetic molecules for therapeutic use [104–106]. Though it is still being debated [104] whether metal-protein interactions are under kinetic [107] or thermodynamic control [108], determining the thermodynamic parameters of the steps thought to be involved in the cascade of naturally occurring events may be a major step for the understanding of the entire process.

View full text